Compare Dow Inc (DOW) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dow Inc vs IDEXX Laboratories, Inc. — how do they compare? Dow Inc trades at $28.46 (market cap $20.65B), while IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B). The key difference: IDEXX Laboratories, Inc. is the larger of the two by market cap, and Dow Inc pays a 4.9% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dow Inc for 82 Days and IDEXX Laboratories, Inc. for 46 Days on average.
| DOW | IDXX | |
|---|---|---|
Market Cap | $20.65B | $40.43B |
Volume | 14,126,943 | 692,164 |
Sector | Basic Materials | Health |
52-Week High | $41.87 | $766.68 |
52-Week Low | $20.65 | $504.70 |
Typical Hold Time | 82 Days | 46 Days |
Enterprise Value | $36.34B | $41.32B |
Dividend Yield | 4.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DOW trades at $28.42, up 2.34% today, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company reported negative net income of -$2.62B in 2025, though it has beaten EPS estimates in recent quarters. Revenue declined to $39.97B in 2025 from $56.9B in 2022, while cash flow from operations dropped significantly. Analyst consensus is a 'Hold' with a $34.22 price target, indicating potential upside from current levels.
The outlook for DOW is cautious due to profitability challenges and declining revenue, offset by positive earnings surprises and a dividend payment. Key risks include margin pressures and high debt levels, while opportunities lie in cost management and market recovery. Investors should weigh the stock's valuation against its financial health and sector headwinds.
IDEXX Laboratories (IDXX) trades at $518.00, up 2.24% with strong earnings beats in recent quarters. The stock shows bearish technical signals but maintains robust fundamentals with 25.03% net margins and 74.21% ROE. Recent acquisitions like CoVetAI and product expansions highlight growth initiatives. Analyst consensus remains bullish with a $665 price target, though technical indicators suggest near-term caution.
Outlook remains positive driven by diagnostic innovation and recurring revenue growth, but faces headwinds from FX volatility and weaker U.S. vet visits. The 36.06 P/E ratio reflects premium valuation, requiring sustained execution. Risks include competitive pressures and insider selling, while institutional ownership trends show mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dow Inc
Dow Inc is a diversified chemical manufacturing company. It combining science and technology to develop innovative solutions that are essential to human progress. Dow's portfolio is comprised of six global business units, organized into three operating segments: Packaging & Specialty Plastics, Industrial Intermediates & Infrastructure, and Performance Materials & Coatings.
Read more on DOW →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
